EPISODE · Sep 29, 2014 · 11 MIN
Glembatumumab Vedotin (CDX-011, CR011-vcMMAE): On The Brink Of Targeted Therapy For Triple-Negative Breast Cancer?
from Journal of Clinical Oncology (JCO) Podcast
A phase I/II study of the antibody-drug conjugate glembatumumab vedotin (CDX-011 or CR011-vcMMAE) in patients with locally advanced or metastatic breast cancer, reveals an acceptable safety profile and promising clinical activity in GPNMB expressing breast cancer.
Embed this episode
NOW PLAYING
Glembatumumab Vedotin (CDX-011, CR011-vcMMAE): On The Brink Of Targeted Therapy For Triple-Negative Breast Cancer?
0:00
11:47
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 11 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on September 29, 2014.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!